Press release
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\nEuropean Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022\n\nTitle: Silencing MMP7 expression with a lung-targeted RNAi molecule limits fibrosis and preserves pulmonary function in bleomycin-injured rats\nPresenter: Erik Bush, Ph.D., Group Vice President, Biology, Arrowhead Pharmaceuticals\n\n2022 Wells Fargo Healthcare Conference – September 7-9, 2022\n\nType: Investor meetings\nPresenter: Vincent Anzalone, CFA, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals\n\nH.C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022\n\nType: Fireside chat presentation\nPresenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals\n\nBaird 2022 Global Healthcare Conference – September 13-14, 2022\n\nType: Fireside chat presentation\nPresenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals\n\nMorgan Stanley 20th Annual Global Healthcare Conference – September 12-14, 2022\n\nType: Fireside chat presentation\nPresenter: Christopher Anzalone, Ph.D., President and CEO, Arrowhead Pharmaceuticals\n\nA copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.\n\nFor more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.\n\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\...